Al Salam Specialty Hospital in Bahrain has introduced a new subcutaneous treatment for multiple sclerosis, marking a medical first in the country under the supervision of Dr. Hani Hameedan.
The hospital announced the rollout of the therapy, which is administered under the skin rather than through intravenous infusion, as a significant step in advancing patient care for individuals living with the chronic neurological condition.
Officials said the shift to subcutaneous delivery aims to improve treatment accessibility and convenience, potentially reducing the burden on patients who previously required frequent hospital visits for infusions.
Dr. Hani Hameedan, who is overseeing the implementation, emphasized that the new approach reflects a broader effort to redefine the patient experience by integrating innovative therapies that align with global standards in neurology care.
The introduction of this treatment option in Bahrain represents a notable advancement in the management of multiple sclerosis, offering patients an alternative that may enhance adherence and quality of life.
Health experts note that expanding access to diverse delivery methods for MS therapies is critical in addressing the long-term needs of those affected by the disease, particularly in regions where specialized care has historically been limited.
The development underscores ongoing efforts across the Gulf region to modernize neurological care and expand access to cutting-edge treatments through specialized medical institutions.
